It is not yet clear what continuous glucose monitoring metrics should be used for a diabetes diagnosis in people with cystic fibrosis.
A new review of studies comparing continuous glucose monitoring (CGM) with oral glucose tolerance tests (OGTT) suggests continuous monitoring would flag more people with cystic fibrosis as having cystic fibrosis-related diabetes (CFRD), but the authors said the existing research base is too fragmented to know how to ensure accurate diagnoses with CGM.
Previous research suggests that as many as half of people with cystic fibrosis will develop diabetes, and the comorbidity can lead to a number of complications, including higher infection risk, faster pulmonary decline, and ultimately higher mortality. Early detection of CFRD is considered critical, since treatment of CFRD can lead to improved lung function and lower mortality rates.
CGM is a technology that tracks patients’ blood glucose over time. It was developed to help patients with diabetes manage their disease, but corresponding author Helena Teede, MBBS, PhD, of Monash University, in Australia, explained along with colleagues that the technology could also be used, in theory, to help detect patients with CFRD, leading to earlier treatment and improved long-term outcomes.
In a new review article in the Journal of Clinical & Translational Endocrinology, Teede and colleagues analyzed the existing scientific literature to find studies comparing CGM to OGTT as tools to detect dysglycemia in people with cystic fibrosis.
The authors found a total of 19 studies that included CGM and OGTT metrics. Together, 416 patients were included in the studies. On CGM, hyperglycemia was defined as having at least one peak sensor glucose reading of at least 200 mg/dL, and dysglycemia was defined as at least one peak sensor glucose reading between 140 and 199 mg/dL.
“CGM hyperglycemia in people with normal or abnormal glucose tolerances was used to define an arbitrary CGM-diagnosis of diabetes,” Teede and colleagues explained.
Though the investigators sought to compare outcomes between CGM and OGTT diagnosis, Teede and colleagues said they opted not to characterize outcomes as being superior or inferior or as having higher or lower sensitivity, since there is not yet international consensus on the use of CGM to screen or diagnose people with CFRD, and since there is no third reference against which to compare CGM and the current gold standard, OGTT.
A comparison of the data in the 16 studies showed the relative risk of an arbitrary CGM diagnosis of diabetes was 2.92 compared to OGTT, but Teede and colleagues cautioned that the studies they analyzed were highly heterogeneous and prone to bias.
The investigators said the ability of CGM to capture long-term data makes it a useful tool to capture a spectrum of glucose abnormalities in people with cystic fibrosis. Still, they concluded that a single reading of 200 mg/dL on CGM is not sufficient to diagnose a patient with CFRD.
Teede and colleagues concluded that more studies are needed to better understand the role CGM could potentially play in monitoring and diagnosing diabetes in people with cystic fibrosis.
“To facilitate high-quality research in this field, firstly reporting of standardized CGM metrics and consensus on definitions for CGM measures of dysglycemia and hyperglycemia in PwCF would be helpful,” they wrote.
In addition, the authors said long-term prospective trials would help investigators better draw links between CGM measures and disease-specific outcomes. They added that data evaluating consumer and healthcare provider experiences would help in the development of guidelines and in the implementation of CGM into clinical practice.
Reference
Kumar S, Pallin M, Soldatos G, Teede H. Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic fibrosis: a systematic review. J Clin Transl Endocrinol. 2022;30:100305. Published 2022 Sep 27. doi:10.1016/j.jcte.2022.100305
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Suggests Walking 10K Steps Daily Improves QOL in Severe Hemophilia
April 12th 2024Among a small group of patients with severe hemophilia, researchers found that getting in more than 10,000 steps each day was linked to significant improvements in perceived physical health and quality of life (QOL).
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
What We’re Reading: Telehealth Debate; STD Rise Among Older Adults; PFAS Limits in Water
April 10th 2024Lawmakers are under pressure to decide the fate of COVID-era telehealth payment changes; the CDC reports an alarming increase in sexually transmitted disease (STD) cases among Americans 55 years and older; new regulations aim to reduce harmful exposure to per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals.”
Read More